Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Module 3 > Immunotherapy in Haematological cancers > Flashcards

Immunotherapy in Haematological cancers Flashcards

1
Q

What is the indirect evidence that there is cancer immunosurveillance?

A

primary immunodeficiency results in high risk of cancer; acquired immunodeficieny-organ transplants and HIV increases risk; tumour infiltration by immune cells correlates with outcome; antibodies and T cells have been foudn specific for cancer somatic mutations; cancers accumulate mutations to evade immune response and secrete immunosuppressor cytokines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which primary immunodeficiencies are linked to high risk of cancer?S

A

CVID; SCID-mice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Give examples of increased cancer risk in organ transplants?

A

10-30x risk of non-melanoma skin cancer; x12 lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Give examples of HIV-1 influencing cancer risk?

A

oncogenic viruses- Kaposi’s sarcoma; lung cancer incidence doubles with low CD4 coutn

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Give an example of the adaptive system being specific for cancer neo-antigens?

A

autologous IgG have been foudn for >2000 neoantigens; CD8 cells against BCR-ABL1 protein in CML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What mutations do cancer cells accumulate to evade the immune response?

A

downregulation or mutation of MHC-I; mutations in beta-2 macroglobulin; downregulation of CD1d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the function of CD1d?

A

presentation of lipid antigens to NKTs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What immunosuppressive cytokines do cancers secrete?

A

IL-10 and TGFb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What receptor do NK and T cells express to eliminate premalignant cells?

A

NKG2D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When is NKG2D upregulated?

A

UV and oncogene, polymorphism in it relates to high cancer rates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the steps of cancer immunoediting?

A

Elimination; equilibrium and escape

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How does allogenic stem cell transplantation work in cancer therapy?

A

give chemotherapy to reduce tumour and immune cells than give donor cells which recognise malignancy as target

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What immune effect does alloSCT harness?

A

graft vs leukaemia effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the evidence that there is graft vs leukaemia effect?

A

T cell depletion increases relapses rates; donor lymphocyte infusion can eliminate minimal residual disease or treat relapse- as can reducing immunsuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the different types of immunotherapy for haematological cancers?

A

vaccines; monoclonal antibodies; CAR T cells; checkpoint inhibition; alloSCT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What determines that clinical efficacy of monoclonal antibodies?

A

target specificity and humanised Mabs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What cells express CD52?

A

all lymphocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the mechanisms of action of anti-CD20 mAbs?

A

ADCC; complement dependent cytotoxicity; direct cytotoxicity; adaptive cellular immunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How does anti-CD20 cause direct cytotoxicity?

A

induction of programmed cell death via a lysosomal pathway after homotypic adhesion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How does anti-CD20 cause adaptive cellular immunity?

A

debris from increased dead cancer cells is taken up by APCs and presented to effectors- ?vaccination effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What cells express FcR and are involved in ADCC?

A

macrophages and NK cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the effect of rituximab in B cell lymphomas?

A

adding rituximab to CHOP therapy increases overall suvival by 13% at 5 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Aside from use as chemoimmunotherapy , how else is rituximab used in haem cancers?

A

maintenance therapy- longer remission and deeper repsonses over time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is rituximab used for in haematology generally?

A

ITP and AHA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
What AI diseases is rituximab used for?
RA; vasculitis; renal disease; EBV infection and post transplant lymphoproliferative disease
26
What is the fully humanised version of anti-CD20?
ofatumumab and obinutuzumab
27
What is the anti-CD52 agent?
alemtuzumab
28
When is alemtuzumab efficacious and what paradigm does this present?
effective in chemotherapy CLL with certain mutations adn demonstrates the use of immunotherapy in chemo-resistant disease; graft T cell depletion in SCT
29
What are the benefits and disadvantages of using alemtuzumab in conditioning for SCT?
minimises risk of GvHD but increases infections and risk of relapse
30
What marker is strongly expressed in plasma cells?
CD38
31
What mAb is used for multiple myeloma?
daratumumab
32
What is the efficacy of daratumumab in multiple myeloma?
36% patients with refractory disease respond; in combination with chemo improves progression free survival at 1 year from 60 to 83%
33
How is elotuzumab thought to work?
ant-SLAM7 which may prime NK cells to attack myeloma ; ADCC
34
Give an example of a toxin conjugate mAb?
brentuximab vedotin
35
What does brentuximab target?
anti-CD30 with a microtubule disrupting agent attached
36
What is brentuximab used for?
relapsed lymphoma- CD30+ T cell lymphoma and relapsed HL
37
What are bispecific T cell engager antibodies?
have 2 specificities e.g anti-CD3 and anti-CD19- one part will stick to tumour cell and then also bind to T cells and activate them
38
What is the name for anti-CD3-anti-CD19 bispecific antibody?
bilatumomab
39
What is bilatumomab used for?
acute lymphoblastic leuakaemia
40
What is the benefit of CAR-T cells?
they aren't dependent on MHC
41
What is a disadvantage of CAR T cells?
only target cell surface antigens ; requires patient to have enough lymphocytes; cytokine storm; neurotoxicity; myelosuppression
42
What is found in the endodomain of CARs?
activator molecules from the TCR e.g the xeta chain as well as co-stimualtory molecules
43
What is found on the extracellular domain of CARs?
Fab portion of hte antibody
44
What is usually the vector for creating CAR T cells?
lentiviruses
45
Why does there need to be host conditioning before CAR-T cell therapy?
to reduce the immunoreaction against the CAR T cells as they cause strong immune reaction
46
When have CAR T cells been shown to be effective?
anti-CD19 CAR-T cells have induced complete remission in 70-85% of patients with relapsed/refractory B cell acute lymphoblastic leukaemia; durable response in refractorydiffuse large B cell lymphoma in 40%
47
What antigen have CAR T cells been targeted against for multiple myeloma?
B cell maturing antigen - specific for plasma cells
48
Give an example of a malignancy where there are CTLA-4 polymorphisms?
myeloma
49
What malignancies over express PD-L1?
solid tumours; myeloma; HL
50
Give an example of an anti-PD1 mAb?
nivolumab
51
What cancers is nivolumab used in ?
melanoma; squamous non-small cell lung cancer ; renal cell carcinoma; HL
52
Is there not a problem with rituximab reducing B cell function?
doesn't appear to cause clinically significant normal B cell and antibody depletion (CD20 not expressed on plasma cells)- only if repeated courses is there a risk of recurrent infection
53
Why are yd T cells effective in anti-tumour effects?
potently cytotoxic and produce IFNy
54
What do the non-redundant role of yd T cells in host protective responses result from?
combination of unique antigen specifities; high clonal frequencies and a pre-activated differentiation status that allows for very rapid repsonses
55
What are the 2 subsets of yd T cells made in the mouse thymus?
IFNy producing and IL-17 producing
56
What have recent reports suggested about the role of IL-17 producing yd T cells in cancer?
tumour-promoting in both mouse and humans
57
What are hte main determinants of yd T cell tumour recognition?
yd TCR; NK cell receptor- NKG2D
58
How does IFNy production enhance tumour cell clearance?
induces upregualtion of MHC-I and enhances CD8 reposnes; inhibits angiogenesis
59
What is the function of IL17 in tumour promotion?
recruits immunsuppressive cells e.g MDSCs or small macropahges which can rpomote angiogenesis, tumour cell grwoth and iTreg differentation
60
How are yd T cells generally split?
according to the Vy chain they use
61
How was the role of yd T cells during tumour development inferred?
comparing tumour progression in yd T cell-deficient mice and wild type mice
62
From mouse KO studies of yd T cells, what was foudn about their role in tumour development?
yd T cell prevented the chmical induced development of papillomas and their progression into squamous cell carinomas; protective against spon B cell lymphoma nad prostate whilst ab T cells promoted tumour progression
63
What does the antitumour cytoxocity of skin resident yd T cells rely on?
both TCR and NKG2D expression
64
What demonstrates the importance of NKG2D in tumours?
high cancer susceptbility in NKG2D deficient mice
65
What is the function of NKg2d?
senses molecular stress signatures that are upegulated on transformed cells
66
How do yd T cells carry out effector functions ?
release perforin and granzymes; express CD95L and TRAIL that engage death receptors; secrete IFNy
67
What surface marker correlates with either IFNy or IL17 production in yd T cells?
CD27+ secrete IFNy whilst CD27- secrete IL17
68
Although some studies have suggested a dentrimental effect to IL-17 producing yd T cells, when have they been shown anti-tumour?
cooperate with BCG vaccination to mediate bladder cancer regression (recruited antitumour neutrophils to the bladder)- which didn't happen in yd defieint and IL-17 deficient mice
69
What cancers have been domsonatrated to show reduced grwoth in yd T cell deficient mice and IL-17 deficient mice?
breast cacner mets and pancreatic intraepithelial neoplasia - correlates with increased angiogenesis due to increased VEGF
70
Give examples of how MDSCs act in a protumour way?
inhibit IFNy and CD8 T cell cytotoxicity
71
Where are yd T cells found in humans?
intestine and dermis
72
What do IL-17 producing yd T cells secrete that recruit MDSCs ?
IL-8; TNF and GM-CSF
73
How is IL-17 yd t cells related to human colorectal cancer?
major sourceo f IL-17 invovledi n chronic inflammation; IL-17 producing yd T cell infiltration positively correlated with clinical stage
74
What causes human yd T cells to produce IL-17?
reqruire a highly inflammatory milieu
75
Why is the concept of boosting type 1 cytotoxic yd T cells in patietns with cancer appealing?
indendent of MHC (tackles a common immune evasion mechanism) and of mutated epitopes (ideal effectors against tumours with low mutation loads)
76
Why are bisphosphonates given before yd T cell therapy?
interfere with phosphoantigen processing enzymes so increase the intracellular levels of them
77
What may limit the clinical performance of yd T cells in cancer therapeutics?
susceptibility to T cell exhaustion and activation induced cell death
78
What may the cause of increased IL-17 yd T cell in human colon cancer?
tumour-induced disruption of the piethlail barrier may induce release of commensal bacterial products leading to activation of DCs, production of IL-23 and differenation into IL_17 yd T cells
79
What is the name for the CTLA-4 mAb ?
ipilumumab (licensed for melanoma)
80
What was the problem with the early vaccine formulation using short peptides?
minimal clinical effectivenness- poor pharmacokinetics leading to rpaid lcearance before DCloading; didn't have an effective DC activating adjuvant- just as likely to induce tolerance as immunity
81
What are the ideal tumour antigens for vaccination?
expressed in the target tumour population in a high number of patients with a cancer; expressed at low levels in normal tissues and should be essential for cancer survival to mimised immune escpe
82
How does onclytic virus therapy work?
employs native or engineered viruses that selectively replicate in and kills cancer cells
83
What are the mechanisms by whch oncolytic viruses function?
acute tumour debulking due to tumour cell infection and lysis, induction/initiation of systemic anti-tumour immunity- can be modified to express specific cytokines that favour immune cell recruitment or produce T cell costimuatlry moelcules on infected tumour cells
84
How can the oncolytic viruses avoid immune killing before they can replicate and infect tumour cells?
PEGylation of the viral coat and polymer coating-preventing antibody binding and neutralisation
85
What oncolytic virus has been approved by the FDC?
T-VEC- modified HSV-1 for advanced melonoma
86
What are the downsides with oncolytic therapy?
immunocompromised patients may not be good candidates as OV-mediated antitumour immunity could be compromised; efficacy in advnaced
87
What is the theory behind adoptive cell therapy?
circumvent the duty of breaking tolerance to tumour antigens and produce a large amount of high avidity effector T cells
88
When ahve autologous TIL infeusions been successful?
melanoma
89
Why is host lymphodepletion thought to improve ACT with TILs?
elimiates immunosuppressive cells- Tregs; MDSCs in tumour microenvironemnt and increasing IL-7 and IL-15
90
Why is there a high immunogenicity of melanoma compared with otehr malignancies?
high frequency of mutational events in the cancer
91
What are hte problems with TIL ACT?
cost; time; lymphodepletion can be life-threatening; only been efficacious in melanoma

Module 3 (33 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions